Xenon Pharmaceuticals Inc. (CIK: 0001582313) EDGAR, Information, Filings... CompaniesBIO.Com

Xenon Pharmaceuticals Inc.

Mailing address
200 - 3650 GILMORE WAY, BURNABY, A1, V5G 48W
Phone
(604) 484-3300
State location
A1
State of incorporation
N/A
Fiscal year end
December 31
SIC
2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
Filings
N/A

Xenon Pharmaceuticals Inc. (CIK: 0001582313) is an American company incorporated in the state of A1. Head office is located at 200 - 3650 GILMORE WAY, BURNABY, A1, V5G 48W. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Xenon Pharmaceuticals Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Gover Justin D.	0001754129	Aug-08-2023	director
Cannon Gillian	0001833910	Aug-08-2023	director
PATOU GARY	0001283535	Jun-02-2023	director
Machado Patrick	0001311210	Jun-02-2023	director
Svoronos Dawn	0001574579	Jun-02-2023	director
GANNON STEVEN	0001643085	Jun-02-2023	director
GAROFALO ELIZABETH A.	0001826361	Jun-02-2023	director
PIMSTONE SIMON N.	0001620084	May-30-2023	director
MORTIMER IAN	0001619961	May-24-2023	director, officer: PRESIDENT & CEO
DiFabio Andrea	0001692506	Nov-07-2022	officer: Chief Legal Officer
KENNEY CHRISTOPHER JOHN	0001880129	Aug-23-2021	officer: Chief Medical Officer
AULIN SHERRY	0001862144	Jun-03-2021	officer: Chief Financial Officer
Von Seggern Christopher	0001821192	Aug-17-2020	officer: Chief Commercial Officer
Desjardins Clarissa	0001793390	Jan-13-2020	director
TARNOW MICHAEL M	0001263647	May-21-2019	director
Hayden Michael R	0001352908	Mar-11-2019	director
AZAB MOHAMMAD	0001309653	Dec-06-2018	director
AYCARDI-FONSECA ERNESTO	0001734218	Mar-19-2018	officer: Chief Medical Officer
BIOTECHNOLOGY VALUE FUND L P	0000918923	Sep-08-2016	other: See Explanation of Responses
BVF PARTNERS L P/IL	0001055947	Sep-08-2016	10 percent owner
BVF INC/IL	0001056807	Sep-08-2016	10 percent owner
BIOTECHNOLOGY VALUE FUND II LP	0001102444	Sep-08-2016	other: See Explanation of Responses
LAMPERT MARK N	0001233840	Sep-08-2016	10 percent owner
Biotechnology Value Trading Fund OS LP	0001660683	Sep-08-2016	other: See Explanation of Responses
BVF Partners OS Ltd.	0001660684	Sep-08-2016	other: See Explanation of Responses
WINQUIST RAYMOND	0001670668	Apr-04-2016	officer: Head, Translational Research
EMPFIELD JAMES R.	0001665430	Feb-08-2016	officer: SVP, Drug Discovery
HOLLER FRANK A	0000938801	May-04-2015	director
Evans Johnston L	0001554661	May-04-2015	director
STEIN EVAN A.	0001620461	Apr-30-2015	director
GOLDBERG Y. PAUL	0001619960	Mar-17-2015	officer: VP, Clinical Development
ROBIN SHERRINGTON	0001619962	Mar-17-2015	officer: SVP Bus. & Corp. Development
COHEN CHARLES J.	0001619967	Mar-17-2015	officer: VP, Biology
CORRAINI KAREN G.	0001619974	Mar-17-2015	officer: Gen. Counsel & Corp. Secretary
SCHELLER RICHARD H	0001214133	Mar-16-2015	director
Bridger Gary	0001600049	Nov-21-2014	officer: EVP, Research & Development
MX Associates, LLP	0001624453	Nov-04-2014	10 percent owner

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Xenon Pharmaceuticals Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
S-3ASR	Document	Automatic shelf registration statement of securities of well-known seasoned issuers Acc-no: 0000950170-24-094855 (33 Act) Size: KB	Aug-09-2024	333-281451 241193747
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000950170-24-094109 (34 Act) Size: KB	Aug-08-2024	001-36687 241189091
8-K	Document	Current report filing Acc-no: 0000950170-24-093933 (34 Act) Size: KB	Aug-08-2024	001-36687 241188307
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0000950170-24-083357 (33 Act) Size: 0 KB	Jul-12-2024	001-36687 241115724
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0000950170-24-072572 (33 Act) Size: 0 KB	Jun-12-2024	001-36687 241039432
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-069468 ( Act) Size: 0 KB	Jun-05-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-069467 ( Act) Size: 0 KB	Jun-05-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-069466 ( Act) Size: 0 KB	Jun-05-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-069465 ( Act) Size: 0 KB	Jun-05-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-069464 ( Act) Size: 0 KB	Jun-05-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-069463 ( Act) Size: 0 KB	Jun-05-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-069462 ( Act) Size: 0 KB	Jun-05-2024
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0000950170-24-069439 (33 Act) Size: 0 KB	Jun-05-2024	001-36687 241023128
S-8	Document	Initial registration statement for securities to be offered to employees pursuant to employee benefit plans Acc-no: 0000950170-24-069340 (33 Act) Size: KB	Jun-05-2024	333-279962 241022283
8-K	Document	Current report filing Acc-no: 0000950170-24-069318 (34 Act) Size: KB	Jun-05-2024	001-36687 241022136
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000950170-24-057139 (34 Act) Size: KB	May-09-2024	001-36687 24931367
8-K	Document	Current report filing Acc-no: 0000950170-24-056940 (34 Act) Size: KB	May-09-2024	001-36687 24930621
ARS	Document	Annual report to security holders Acc-no: 0000950170-24-049201 (34 Act) Size: KB	Apr-26-2024	001-36687 24884262
DEF 14A	Document	Definitive proxy statements Acc-no: 0000950170-24-049198 (34 Act) Size: KB	Apr-26-2024	001-36687 24884236
8-K	Document	Current report filing Acc-no: 0000950170-24-046023 (34 Act) Size: KB	Apr-19-2024	001-36687 24858048

Recent 20 filings. View all Xenon Pharmaceuticals Inc. filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Xenon Pharmaceuticals Inc. overview
Xenon Pharmaceuticals Inc. job
Xenon Pharmaceuticals Inc. stock
Xenon Pharmaceuticals Inc. ownership
Xenon Pharmaceuticals Inc. CEO
Xenon Pharmaceuticals Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.